title: Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells.
abstract: An emerging treatment option for chronic lymphocytic leukemia (CLL) is to make cytotoxic immune cells express a chimeric antigen receptor (CAR) that recognizes specific surface molecules on CLL cells. Here an mRNA coding for an anti-CD19 CAR was transfected into the NK-92 cell line by electroporation. In contrast to cDNA, mRNA resulted in high transfection efficiency (47.2 +/- 8% versus <5% for cDNA) with minimal effect on cell viability. NK-92 cells expressing anti-CD19 CAR killed previously resistant CD19+ B-ALL cell lines, as well as primary CLL cells and therefore may present a safe, cell-based, targeted treatment for patients with CLL.
authors.affiliation: Molecular Oncology Research Institute-Tufts Medical Center, 800 Washington Street-Box 5609, Boston, MA 02111, USA. lboissel@tuftsmedicalcenter.org
authors.forename: Laurent
authors.initials: L
authors.lastname: Boissel
authors.forename: Monica
authors.initials: M
authors.lastname: Betancur
authors.forename: Winfried S
authors.initials: WS
authors.lastname: Wels
authors.forename: Hande
authors.initials: H
authors.lastname: Tuncer
authors.forename: Hans
authors.initials: H
authors.lastname: Klingemann
mesh_terms: D018941:Antigens, CD19 / Q000235:genetics*; D001483:Base Sequence; D045744:Cell Line, Tumor; D017931:DNA Primers; D018274:Electroporation; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology*; D012333:RNA, Messenger / Q000235:genetics*; D011993:Recombinant Fusion Proteins / Q000235:genetics; D014162:Transfection
chemical_list: D018941:Antigens, CD19; D017931:DNA Primers; D012333:RNA, Messenger; D011993:Recombinant Fusion Proteins